Innovative Combination Therapy Shows Promise for Bladder Cancer Patients Unresponsive to Standard Treatment
Moffitt Cancer CenterIn a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.